229 related articles for article (PubMed ID: 27207774)
1. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System.
Janku F; Huang HJ; Claes B; Falchook GS; Fu S; Hong D; Ramzanali NM; Nitti G; Cabrilo G; Tsimberidou AM; Naing A; Piha-Paul SA; Wheler JJ; Karp DD; Holley VR; Zinner RG; Subbiah V; Luthra R; Kopetz S; Overman MJ; Kee BK; Patel S; Devogelaere B; Sablon E; Maertens G; Mills GB; Kurzrock R; Meric-Bernstam F
Mol Cancer Ther; 2016 Jun; 15(6):1397-404. PubMed ID: 27207774
[TBL] [Abstract][Full Text] [Related]
2. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.
Janku F; Claes B; Huang HJ; Falchook GS; Devogelaere B; Kockx M; Bempt IV; Reijans M; Naing A; Fu S; Piha-Paul SA; Hong DS; Holley VR; Tsimberidou AM; Stepanek VM; Patel SP; Kopetz ES; Subbiah V; Wheler JJ; Zinner RG; Karp DD; Luthra R; Roy-Chowdhuri S; Sablon E; Meric-Bernstam F; Maertens G; Kurzrock R
Oncotarget; 2015 Sep; 6(29):26886-94. PubMed ID: 26330075
[TBL] [Abstract][Full Text] [Related]
3. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.
Melchior L; Grauslund M; Bellosillo B; Montagut C; Torres E; Moragón E; Micalessi I; Frans J; Noten V; Bourgain C; Vriesema R; van der Geize R; Cokelaere K; Vercooren N; Crul K; Rüdiger T; Buchmüller D; Reijans M; Jans C
Exp Mol Pathol; 2015 Dec; 99(3):485-91. PubMed ID: 26407762
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
5. Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues.
Schiefer AI; Parlow L; Gabler L; Mesteri I; Koperek O; von Deimling A; Streubel B; Preusser M; Lehmann A; Kellner U; Pauwels P; Lambin S; Dietel M; Hummel M; Klauschen F; Birner P; Möbs M
J Mol Diagn; 2016 May; 18(3):370-377. PubMed ID: 26921540
[TBL] [Abstract][Full Text] [Related]
6. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
Bisschop C; Ter Elst A; Bosman LJ; Platteel I; Jalving M; van den Berg A; Diepstra A; van Hemel B; Diercks GFH; Hospers GAP; Schuuring E
Melanoma Res; 2018 Apr; 28(2):96-104. PubMed ID: 29232304
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.
Lade-Keller J; Rømer KM; Guldberg P; Riber-Hansen R; Hansen LL; Steiniche T; Hager H; Kristensen LS
J Mol Diagn; 2013 Jan; 15(1):70-80. PubMed ID: 23159593
[TBL] [Abstract][Full Text] [Related]
8. Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.
Jurkowska M; Gos A; Ptaszyński K; Michej W; Tysarowski A; Zub R; Siedlecki JA; Rutkowski P
Int J Clin Exp Pathol; 2015; 8(7):8487-93. PubMed ID: 26339422
[TBL] [Abstract][Full Text] [Related]
9. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.
Möhrmann L; Huang HJ; Hong DS; Tsimberidou AM; Fu S; Piha-Paul SA; Subbiah V; Karp DD; Naing A; Krug A; Enderle D; Priewasser T; Noerholm M; Eitan E; Coticchia C; Stoll G; Jordan LM; Eng C; Kopetz ES; Skog J; Meric-Bernstam F; Janku F
Clin Cancer Res; 2018 Jan; 24(1):181-188. PubMed ID: 29051321
[No Abstract] [Full Text] [Related]
10. Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue.
Johnston L; Power M; Sloan P; Long A; Silmon A; Chaffey B; Lisgo AJ; Little L; Vercauteren E; Steiniche T; Meyer T; Simpson J
J Clin Pathol; 2018 Apr; 71(4):336-343. PubMed ID: 28899979
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600 mutations and pathological features in Japanese melanoma patients.
Yamazaki N; Tanaka R; Tsutsumida A; Namikawa K; Eguchi H; Omata W; Oashi K; Ogawa T; Hayashi A; Nakamura N; Tsuta K
Melanoma Res; 2015 Feb; 25(1):9-14. PubMed ID: 25051202
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.
Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES
Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992
[TBL] [Abstract][Full Text] [Related]
13. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
Gonzalez-Cao M; Mayo-de-Las-Casas C; Molina-Vila MA; De Mattos-Arruda L; Muñoz-Couselo E; Manzano JL; Cortes J; Berros JP; Drozdowskyj A; Sanmamed M; Gonzalez A; Alvarez C; Viteri S; Karachaliou N; Martin Algarra S; Bertran-Alamillo J; Jordana-Ariza N; Rosell R
Melanoma Res; 2015 Dec; 25(6):486-95. PubMed ID: 26366702
[TBL] [Abstract][Full Text] [Related]
14. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG
PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669
[TBL] [Abstract][Full Text] [Related]
16. Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma.
Sener E; Yildirim P; Tan A; Gokoz O; Tezel GG
Pathol Res Pract; 2017 May; 213(5):522-530. PubMed ID: 28216139
[TBL] [Abstract][Full Text] [Related]
17. BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.
Tatsuno M; Shioda Y; Iwafuchi H; Yamazaki S; Iijima K; Takahashi C; Ono H; Uchida K; Okamura O; Matubayashi M; Okuyama T; Matsumoto K; Yoshioka T; Nakazawa A
Diagn Pathol; 2016 Apr; 11():39. PubMed ID: 27094161
[TBL] [Abstract][Full Text] [Related]
18. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.
Board RE; Ellison G; Orr MC; Kemsley KR; McWalter G; Blockley LY; Dearden SP; Morris C; Ranson M; Cantarini MV; Dive C; Hughes A
Br J Cancer; 2009 Nov; 101(10):1724-30. PubMed ID: 19861964
[TBL] [Abstract][Full Text] [Related]
19. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
[TBL] [Abstract][Full Text] [Related]
20. Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600).
Skorokhod A; Helmbold P; Brors B; Schirmacher P; Enk A; Penzel R
PLoS One; 2013; 8(3):e59221. PubMed ID: 23555633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]